Shares of Pfizer Inc. (NYSE:PFE) ended Friday session in red amid volatile trading. The shares closed down -0.62 points or -1.79% at $34.10 with 6.07 billion shares getting traded. Post opening the session at $34.55 the shares hit an intraday low of $34.09 and an intraday high of $34.59 and the price vacillated in this range throughout the day. The company has a market cap of $203.15 billion and the numbers of outstanding shares have been calculated to be 6.07 billion shares.
Pfizer Inc. (PFE) on September 7, 2016 announced that Dr. Ole Isacson, a world-renowned scientist and thought leader in neurology, will become Chief Scientific Officer of the Neuroscience Research Unit and Senior Vice President, effective September 16. Dr. Isacson is a Professor of Neurology at Harvard Medical School, and will continue to serve in an educational role. He is also a founding director of the Neuroregeneration Institute at McLean Hospital. Dr. Isacson will report directly to Mikael Dolsten, President of Worldwide Research and Development.
Dr. Isacson received his Medical Bachelor and Doctor of Medicine degrees from the University of Lund in Sweden and held a two year postdoctoral fellowship at Cambridge University in England before joining Harvard in 1989. Over the course of two decades, his lab has become known as one of the most recognized academic research centers for Parkinson’s disease and other neurodegenerative disorders.
“Dr. Isacson’s deep expertise in neurodegenerative disorders is well-aligned with our work in Alzheimer’s and Parkinson’s disease, where we are working to advance potential breakthrough therapies to fill the tremendous unmet need that exists for patients,” said Dr. Dolsten. “In addition, his strong ties in the local academic community will be important as our Cambridge site continues to drive collaborations with leading scientific and academic institutions that can help us speed the pace of discovery.”
Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) ended Friday session in red amid volatile trading. The shares closed down -1.90 points or -6.34% at $28.06 with 341.19 million shares getting traded. Post opening the session at $29.57 the shares hit an intraday low of $28.05 and an intraday high of $29.57 and the price vacillated in this range throughout the day. The company has a market cap of $8.97 billion and the numbers of outstanding shares have been calculated to be 341.19 million shares.
On Sept. 6, 2016 Valeant Pharmaceuticals International, Inc. (VRX) and Progenics Pharmaceuticals, Inc. (PGNX) announced the U.S. commercial launch of RELISTOR® (methylnaltrexone bromide) Tablets, which is now available for prescribing. RELISTOR Tablets (450 mg once daily) were approved by the U.S. Food and Drug Administration (FDA) for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain on July 19, 2016 .
“We are very pleased to launch RELISTOR Tablets in the U.S. and provide an exceptional new treatment option for the millions of patients who suffer from extreme discomfort due to OIC,” said Joseph C. Papa , Chief Executive Officer of Valeant. “This new method of delivery for RELISTOR offers healthcare professionals a novel alternative to address the treatment of OIC – a growing need in pain management – and demonstrates Valeant’s continued commitment to delivering innovative products that improve people’s lives.”